Mike Sherman, Chimerix CEO
Chimerix places its bets on Oncoceutics' dopamine antagonist for rare brain cancer in quest to salvage its image
In the clinical wasteland of aggressive brain cancers, Philly’s Oncoceutics has churned out promising data with a Phase II candidate on the verge of an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
